A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Study ID
- NCT05610280
- Phase
- PHASE3
- Status
- Completed
Conditions
- Atherosclerosis
- Cardiovascular Diseases
- Hypertriglyceridemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Olezarsen — DRUGOlezarsen will be administered by SC injection.
- Placebo — DRUGOlezarsen-matching placebo will be administered by SC injection.
Study Details
The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
Key Dates
- Start date
- Nov 21, 2022
- Status verified
- Feb 2026
- Primary completion
- Aug 8, 2024
- Completion
- Jun 9, 2025
Study Design
- Enrollment
- 1,478 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: OlezarsenParticipants will be randomized to receive multiple doses of olezarsen, once every 4 weeks by subcutaneous (SC) injection up to Week 49.
- Placebo Comparator: PlaceboParticipants will be randomized to receive olezarsen-matching placebo, once every 4 weeks by SC injection up to Week 49.
Primary Outcome Measure
Percent Change From Baseline to Week 25 in Fasting Triglycerides (TG) Compared to Placebo [ Time Frame: Baseline to Week 25 ]
Locations (68)
Find similar trials in Birmingham, AL
By research site
Alabama Clinical Therapeutics, LLC Alabaster· Birmingham, ALHeart Center Research PC· Huntsville, ALCardiovascular Research Foundation of Southern California· Beverly Hills, CAWestside Medical Associates of Los Angeles· Beverly Hills, CADiabetes/Lipid Management & Research Center· Huntington Beach, CAUniversity of California, San Diego (UCSD)· La Jolla, CA
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Causes and Natural History of DyslipidemiasRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Cardiovascular BiorepositoryEnrolling By Invitation · Kenneth S. Campbell · Lexington, Kentucky
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia